Skip to main content

Dyne Therapeutics, Inc 8-K, filed Nov 5, 2026

Dyne Therapeutics, Inc. (DYN)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

Dyne Therapeutics, Inc filed this 8-K on November 5, 2026.

Dyne Therapeutics, Inc. reported a $193.6 million quarterly net loss and $1.134 billion in cash, cash equivalents and marketable securities, with funding expected into the second quarter of 2028; z-rostudirsen’s FDA PDUFA target action date is January 21, 2027. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits